Understanding The Potential Role of PABPN1 in Disease (G8106)

Target Name: PABPN1

NCBI ID: G8106

PABPN1

Understanding The Potential Role of PABPN1 in Disease

PABPN1 (PABPN1 variant 1) is a gene that has been identified as a potential drug target or biomarker for the treatment of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. PABPN1 is a protein that is expressed in many tissues and cells in the body, including the brain, and is involved in the development and maintenance of blood-brain barrier (BBB).

The PABPN1 gene was first identified in 2006 using genomic screening techniques, and has since been shown to be involved in the regulation of various cellular processes, including cell adhesion, migration, and survival. PABPN1 has also been shown to be involved in the development and progression of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

One of the key challenges in studying PABPN1 is its expression and function in different tissues and cells. While PABPN1 is highly expressed in many tissues and cells in the body, its expression and function can vary depending on the specific context. For example, PABPN1 is highly expressed in the brain, and is thought to be involved in the development and maintenance of the BBB. However, its expression and function in other tissues and cells may be different.

In addition to its potential drug target or biomarker properties, PABPN1 is also of interest as a potential therapeutic target for various diseases. For example, PABPN1 has been shown to be involved in the development and progression of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. Therefore, targeting PABPN1 may be a promising strategy for the treatment of these diseases.

Another potential application of PABPN1 is its potential as a biomarker for cancer. PABPN1 has been shown to be expressed in various types of cancer, including breast, lung, and ovarian cancer. Therefore, targeting PABPN1 may be a promising strategy for the detection and treatment of cancer.

In conclusion, PABPN1 is a gene that has potential as a drug target or biomarker for the treatment of various diseases. Its expression and function in different tissues and cells make it an attractive target for research into the mechanisms underlying its role in disease. Further research is needed to fully understand the role of PABPN1 in disease and to develop effective treatments.

Protein Name: Poly(A) Binding Protein Nuclear 1

Functions: Involved in the 3'-end formation of mRNA precursors (pre-mRNA) by the addition of a poly(A) tail of 200-250 nt to the upstream cleavage product (By similarity). Stimulates poly(A) polymerase (PAPOLA) conferring processivity on the poly(A) tail elongation reaction and controls also the poly(A) tail length (By similarity). Increases the affinity of poly(A) polymerase for RNA (By similarity). Is also present at various stages of mRNA metabolism including nucleocytoplasmic trafficking and nonsense-mediated decay (NMD) of mRNA. Cooperates with SKIP to synergistically activate E-box-mediated transcription through MYOD1 and may regulate the expression of muscle-specific genes (PubMed:11371506). Binds to poly(A) and to poly(G) with high affinity (By similarity). May protect the poly(A) tail from degradation (By similarity). Subunit of the trimeric poly(A) tail exosome targeting (PAXT) complex, a complex that directs a subset of long and polyadenylated poly(A) RNAs for exosomal degradation. The RNA exosome is fundamental for the degradation of RNA in eukaryotic nuclei. Substrate targeting is facilitated by its cofactor MTREX, which links to RNA-binding protein adapters (PubMed:27871484)

The "PABPN1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PABPN1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets